Admitted Multimorbid Patients
Conditions
Keywords
pharmacogenetics, implementation, medication review
Brief summary
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
Detailed description
Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone. The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward. The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.
Interventions
GENETICPharmacogenetic test
genotyping for genes that affect drug metabolism
OTHERMedication review
systematic and interdisciplinary method aiming to increase quality of medication treatment
Sponsors
University Hospital, Akershus
Diakonhjemmet Hospital
University of Oslo School of Pharmacy
Hospital Pharmacy Enterprise, South Eastern Norway
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* at least 2 long-term conditions * at least 5 regular drugs of which at least one relevant for pharmacogenetic testing * at least 2 years life expectancy * able to communicate in Norwegian * able to give informed consent * summary care record
Exclusion criteria
* moderate to severe dementia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with results from pharmacogenetic testing included in medication review | from admission to discharge, an average of 1 week | Number of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acceptance of recommendations | after medication review and before discharge, an average of 3 days | Degree of acceptance of recommendations after pharmacogenetic testing, by prescribers |
| Documentation of information from pharmacogenetic testing | after medication review and before discharge, an average of 3 days | Number of patients with information from pharmacogenetic testing documented in the patient journal |
Countries
Norway
Outcome results
None listed